Buy & Sell Nomura Holdings Inc (NMR) – Nomura Holdings Inc Price Today
Aura AI Summary
Key Stats
- $23.65BMarket Cap
- FinancialsSector
- -14.45%3M Drawdown
- -Enterprise Value
- 5.07%Dividend Yield
- 1% Buy | 99% SellTrading Activity
- 39 daysTypical Hold Time
Nomura Holdings Inc (NMR) is currently valued at a market capitalization of $23.65B. Over the past 52 weeks, Nomura Holdings Inc has traded between a low of $6.03 and a high of $9.54, highlighting its annual price range. Over the past three months, Nomura Holdings Inc has recorded a drawdown of -14.45%, reflecting recent price volatility. Nomura Holdings Inc offers a dividend yield of 5.07%, with the most recent dividend of $0.24 paid on 31 Mar 25. On average, investors hold Nomura Holdings Inc for approximately 39 days, indicating typical investor behavior on the platform.
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Most Recent News
ISS wins 7-year contract to provide 25,000 daily school meals in West Sussex, UK
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
argenx to present at major investor conferences in June, highlighting growth and new treatments.
argenx, a global immunology company focused on autoimmune diseases, announced its management team will present at two key investor conferences in June: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Hea...
Capgemini targets 5.5-7.5% revenue CAGR by 2028, driven by AI transformation and margin expansion.
Capgemini announced its strategic direction focused on leveraging agentic AI to drive enterprise-wide transformation and business value. The company aims for a 5.5% to 7.5% compound annual revenue growth rate from 2025 to 2028, with margin expansion ...